rss
Br J Ophthalmol 2006;90:1440-1441
  • Letter

The International Intravitreal Bevacizumab Safety Survey

  1. F Ziemssen,
  2. S Grisanti,
  3. K U Bartz-Schmidt
  1. University Eye Hospital Tuebingen, Tuebingen, Germany
  1. Correspondence to: F Ziemssen University Eye Hospital Tuebingen, Schleichstr 12, D-72076 Tuebingen, Germany; Focke.Ziemssen{at}med.uni-tuebingen.de
  • Accepted 15 August 2006

We read with interest the article by Fung et al1 assessing complications related to single or repeat intravitreal injections of bevacizumab. We congratulate the authors on studying this innovative treatment via the internet and greatly appreciate the effort to gather timely information about the potentially related adverse events. When using a product for an indication not in the approved label, doctors have the responsibility to be well informed about the product and its potential risks, and to base its use on firm scientific rationale and sound medical evidence.2 Informed consent must also depend on a full discussion of all potential complications of the treatment proposed. Unfortunately, some pitfalls of this survey have restricted the explanatory power of the presented results.3

The definition of the study population remains …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.